



MASARYKOVA UNIVERZITA

Design sekvence PCR primerů

Hana Konečná

CEITEC - MU

Centrální laboratoř - Proteomika

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.



INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ



SYNTEZICKÉ OLIGONUKLEOTIDY

MASARYKOVA UNIVERZITA

- definice
- aplikace
- modifikace
- syntéza
- purifikace
- kontrola kvality

OLIGONUKLEOTIDY

- design sekvence
- zásady navrhování
- software OLIGO 7
- praktická ukázka

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.




INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

Aplikace syntetických oligonukleotidů

- primery pro syntézu komplementární DNA
PCR, Real-Time PCR
- syntéza genů a rekombinantní proteiny
- hybridizační sondy pro klonování
- místně cílená mutageneza
- sekvenování a genetické profilování
- diagnostika – testy a biosensory
- gene arrays
- blokace genové exprese *antisense oligo*
- potenciální léčiva a DNA vakcíny
- NMR studia interakcí DNA-protein
- strukturální rentgenová analýza NA

Modifikace

- degenerace
- konce řetězce
- báze
- fosfát
- cukr
- PNA



Degenerované oligonukleotidy

Příklady:

ACG TAC GTA CGT ACG TAC
nedegenerovaný

ACG T**M** GTA CGT ACG TAC

M = A/C

ACG TAC GTA C**D**T ACG TAC

D = A/G/T

ACG TAC GTA CGT ACG **N**AC

N = A/C/G/T

Degenerované oligonukleotidy

2-deoxyinosin

M	A or C
R	A or G
W	A or T
S	C or G
Y	C or T
K	G or T
V	A or C or G
H	A or C or T
D	A or G or T
B	C or G or T
N	G or A or T or C
X	G or A or T or C

Modifikace na 5'-konci

postsyntetické modifikace →



sekvenování →
fragmentační analýza
gene arrays
Real-Time PCR

5'

fosforylace

aminoskupina

thioskupina

digoxigenin

biotin

enzymy

psoralen

akridin

cholesterol

fluoresc. barviva

zhášedla

2,4-dinitrofenyl

TBR-chelát

spacer

větvení

blokáda



Modifikace na 3'-konci

derivatizovaná matrice



3'

fosfát

thioskupina

aminoskupina

spacer

akridin



biotin



fluoresc.barviva



zhášedla


cholesterol

2,4-dinitrofenyl




Real-Time PCR


- 2x značená sonda
- REPORTER
- QUENCHER




2. **Strand displacement:** When the probe is intact, the reporter dye emission is quenched.



3. **Cleavage:** During each extension cycle, the DNA polymerase cleaves the reporter dye from the probe.



4. **Polymerization completed:** Once separated from the quencher, the reporter dye emits its characteristic fluorescence.



Další modifikace

fosforothioáty
fosforodithioáty
H-fosfonáty
metylfosfonáty


← páteř

cukr →


modifikace v 2' pozici
modifikace ribóзовé jednotky

Terapeutika


→ nedegradována nukleázami!
modifikace fosfodiesterové vazby




phosphorothioate




methylphosphonate




phosphoramidate



3'-thioformacetal




methylene(methyliminio)



boranophosphate

ANTISENSE oligonukleotid

- oligonukleotid nebo analog
- komplementární k segmentu RNA nebo DNA
- vazbou inhibuje jejich normální funkci




Peptidonukleová kyselina **PNA**

DNA

- nenabitá molekula
- vazba k DNA/RNA


N-(2-aminoethyl)-glycin →



Peptidonukleová kyselina

- nenabitá molekula
- vazba k DNA/RNA

N-(2-aminoethyl)-glycin →




Vlastnosti PNA

- vysoká termostabilita
- T_m nezávisí na obsahu solí
- vyšší specifita
- vyšší afinita
- rezistentní k enzymům...

LNA

Locked Nucleic Acid

2'-O, 4'-C methylenový můstek
potlačená flexibilita ribofuranózového kruhu
struktura je **zamčena** do rigidní C3-endo konformace
zlepšená hybridizace
výjimečná biostabilita



OLIGONUKLEOTIDY

design

syntéza


purifikace




EXPEDITE 8909

Syntéza oligonukleotidu

- syntéza na pevné fázi
- od 3'-konce k 5'-konci
- bezvodé prostředí



Kontrola kvality





- HPLC
- Perfúzní chromatografie

- anex
- RP

Perfúzní chromatografie


klasický sorbent

POROS




Maldi-TOF MS

CE




VÝTĚŽEK



Efficiency


- 0.995
- 0.990
- 0.980

PAGE



PURIFIKACE

- Sephadex
- RP cartridge
- HPLC




DESIGN OLIGONUKLEOTIDU

- manuální
- počítačový

www.protocol-online.org/prot/Research_Tools/Online_Tools/Oligo_Design/index.html

Hlavní kritéria pro sekvenci PCR primeru

- vysoce specifické
- netvoří dimery a vlásenky
- stabilní duplexy s aktivní sekvencí
- nepřiliš stabilní 3'-konec



OLIGO 6

- PCR primery,
- hybridizační sondy
- sekvenační primery

OLIGO 7 (od roku 2008)


- TaqMan sondy
- primery pro *nested PCR*
- *molecular beacons*
- siRNA


5' CTT CTG CTC AAT CTT TCT AC 3' FORWARD

+ 5' 1 ATGGCTTCTG CTC AATCTTT CTAC AACCAA AGCTCTGTCT TGAAAATCAA
 51 TGTCATGGTT GTGGACGATG ATCATGTTTT CTTGATATC ATGTCACGCA
 101 TGCTTCAACA CTCCAAATAC AGAGGTAATT AAATATTATT ATCATATTAT
 151 ATATAATATG TTATTGATTT TTTGTTTGTG ATTTCAATTA GATTTTTATT
 201 TCTATGATTT CTTAGCATGA AATACAATTT TTGGAGAAAC AACTAGCAGT
 251 TTTAAAAACA AAACCTTGAAT TTTGAGAAAT TCAAAGATGT TATATATATA
 301 TGTCAAAATT TAACAATTAT TCTTCTAAAT CATCCGGATT CCGTTTACAT
 351 GTACACATCT ACAATTTTCA ATTGAGGTAT TCTTGTTTTG ATGCCTTTGA
 401 GACGAATAGT TTGATTGATA AAAAAAATTC TAACCAATAT GATATATAAA
 451 GTTTTATTTT TTTTTGTCAA ACCATACTTT AACTATGTA ACTTTTTTAA
 501 GAGATTATTG AAAATAGTTT ATTTATAAAA TAGTAACCTA TTGTTGAATT
 551 AAAAAAATAA AAAAAATTGT AAATCGTGTG TGCAAACGAC ATGTGATTTA
 601 TCTTAGTTTT AACTAGCTG ATATTCTTCA AATCGACTGT TCTTATAAGT
 651 AATCAACCAA TTAGCATCAA TCACAATAAA TTGTAAACAC TTCAATGAAA
 701 ATGGTGATTT TAAAGAATAT GTTTTACTTA TGTTATGAAC TATCTCAAAT
 751 TTGTGAAATA TTTCATAACT AATGTGAAA ACTATATAAC CCCTCCATAC
 801 AAAACGTAAG TAAAATTTAT GAAATCCTAT CATTTTTTAAA GGTTAAACCA
 851 ATCAAAAAGT AATAATTCTT GGTACTTGCA ATATTTTTGT CATTATATTT
 901 TAGTTTATTA ATTTTATTTT GATTAAATGG TTTTAGATCC ATCAGTTATG
 951 GAGATCGCAG TTATAGCTGT AGACGATCCG AAGAAAGCAT TATCTACTCT
 1001 AAAAATTCOA CGAGACAATA TAGATCTCAT AATCACAGAT TATTATATGC
 1051 CTGGTATGAA CGGTTTACAA CTCAAAAAAC AAATCACTCA GGAATTTGGA
 1101 AATTTACCGG TCTTAGGTAA CATTTTTTGT TCTTTACAAC TTAAATTTAA

3'

5' TGA AGA ATA TCA GCT AGT TT 3' REVERSE





PCR

File: Human 4E.seq

Optimal Annealing Temperature: 50.8 °C (Max: 66.3 °C)

	Position and Length		T_m [°C]	GC [%]	P.E.#	Score
Product	862		78.9	29.6	n/a	697
Forward Primer	918	22	56.9	45.5	471 / 471	840
Reverse Primer	1753	27	55.3	29.6	489 / 489	834
Upper Oligo	979	24	56.5	33.3	479 / 479	917
Lower Oligo	1694	23	55.4	39.1	457 / 457	841

Product T_m - Reverse Primer T_m : 23.6 °C
 Primers T_m difference: 1.6 °C Comments:

	Concentration	
Forward Primer	200.0	nM
Reverse Primer	200.0	nM
Upper Oligo	200.0	nM
Lower Oligo	200.0	nM
Monovalent Cation	50.0	mM
Free Mg[2+]	0.7	mM

Total Na[+] Equivalent: 155.8 mM

Selected Primers	
File: BRCA2 gene.seq	
AY436640:15438F22	AY436640:15917R20
5' CAATATATACCGTAGTCCCCTA 3'	5' CAGCTACATATTACGCCAGA 3'
Length: 22-mer	Length: 20-mer
Score: 802 points	Score: 914 points
5' Position: 15438	3' Position: 15917
T_m/t_m : 53.4 52.6 °C	T_m/t_m : 53.1 53.8 °C
$\Delta G/\Delta g$ (25 °C): -30.5 -29.2 kcal/mol	$\Delta G/\Delta g$ (25 °C): -28.6 -28.5 kcal/mol
$\Delta S/\Delta s$: -472.1 -449.5 cal/°K * mol	$\Delta S/\Delta s$: -430.5 -419.6 cal/°K * mol
$\Delta H/\Delta h$: -171.3 -163.2 kcal/mol	$\Delta H/\Delta h$: -157.0 -153.6 kcal/mol
3' ΔG : -6.5 kcal/mol	3' ΔG : -6.9 kcal/mol
Degeneracy: 1	Degeneracy: 1
P.E.#: 443/443	P.E.#: 477/477
1/E: 4.63 nmol/A ₂₆₀ 31.1 µg/A ₂₆₀	1/E: 5.05 nmol/A ₂₆₀ 31.0 µg/A ₂₆₀

Priming Efficiency PE Score





Current Oligo Hairpin Stems


File: BRCA2 gene.seq

Current Oligo 21-mer [5042]



1. # of paired bases = 5; loop = 5 nt; $\Delta G = -3.0$ kcal/mol; $T_m = 54.6$ °C



2. # of paired bases = 6; loop = 5 nt; $\Delta G = 0.2$ kcal/mol; $T_m = 21.7$ °C



3. # of paired bases = 4; loop = 2 nt; $\Delta G = 0.9$ kcal/mol; $T_m = 8.7$ °C



Reverse Primer False Priming Sites

File: M13MP18

Reverse Primer M13MP18:6310R19 (positive strand)
 Priming efficiency of the perfect match is 482 (above the threshold)

Priming efficiency: 482 (above the threshold)

```

5' (6328) GGTTTTCCCAGTCACGACG (6310)3'
          |||
3' (6328) ccaaagggtcagtgctgc (6310)5'
    
```

Priming efficiency: 244 (above the threshold)

```

5' (6328) GGTTTTCCCAGTCACGACG (6310)3'
          |||
3' (626) agcaaatgggtc--tgctgc (610)5'
    
```

Priming efficiency: 193 (above the threshold)

```

5' (6328) GGTTTTCCCAGTCACGACG (6310)3'
          |||
3' (5125) tctaagtgggtcagtg-tgc (5108)5'
    
```



Forward Primer Composition

File: BRCA2 gene.seq

Forward Primer AY436640:6275F19

T _d	64.2°	[nearest neighbor method]
T _m	56.5°	[nearest neighbor method]
T _m	70.8°	[%GC method]
T _m	56°	[2(A+T) [°] + 4(G+C) [°] method]
T _m (RNA)[1M Na]	81°	[%GC method]
T _m (DNA:RNA)[1M Na]	74.7°	[%GC method]
A ₂₆₀ /A ₂₈₀	1.59	[single strand]
Molecular Weight	5.8K	[one strand]
Molecular Weight	11.7K	[two strands]
µg/OD	47.4	[dsDNA]

Base	Number	%
A	2	[10.5%]
C	5	[26.3%]
G	4	[21.1%]
T	8	[42.1%]
A + T	10	[52.6%]
G + C	9	[47.4%]

Oligonucleotide Database

File: NewDatabase.odb

of Records: 29

#	Date	ID Number	Sequence	3'-Dim. ΔG	P.E. / p.e.	Tm / t _m
<input type="checkbox"/> 21	12/02/06	AY436640:5916R19	AATGCCTGCCTTTAGTCTG	- SC	430 430	54.1 54.5
<input type="checkbox"/> 22	12/02/06	AY436640:5916R20	CAATGCCTGCCTCTAGTCTG	0.3 SC	366 450	50.9 57.2
<input type="checkbox"/> 23	12/02/06	AY436640:5937R21	TCAATTTCTTTAGCTTGCCAT	0.3 SC	449 449	54.7 53.1
<input checked="" type="checkbox"/> 24	12/02/06	AY436640:5937R22	TTCAATTTCTTTAGCTTGCCAT	0.3 SC	458 458	55.9 53.8
<input type="checkbox"/> 25	12/02/06	AY436640:4695U22	TGCCTTAACAAAAGTAATCCAT	0.3 SC	432 432	54.5 53.0
<input type="checkbox"/> 26	12/02/06	AY436640:5325U22	AATTACGTCTTTCTTATGCCAA	0.3 SC	453 453	53.3 53.0
<input type="checkbox"/> 27	12/02/06	AY436640:5786L23	CTCTGCCTAGAACATTATCACTC	-0.3 SC	451 451	54.8 55.0
<input type="checkbox"/> 28	12/02/06	AY436640:5860L19	AACAACCAAAGCCAACCTG	-0.9 SC	444 444	55.3 55.9

Oligonucleotide Sets (64)


#	Forward Primer	Reverse Primer	Upper Oligo	Lower Oligo
1	2	3	4	
<input type="checkbox"/> 36	8	23	25	28
<input type="checkbox"/> 42	8	24	25	28
<input checked="" type="checkbox"/> 47	9	14	25	27
<input type="checkbox"/> 39	9	15	25	27
<input type="checkbox"/> 33	9	16	25	27
<input type="checkbox"/> 61	9	17	25	27
<input type="checkbox"/> 48	9	18	25	27


This database is linked to BRCA2 gene.seq

Selected oligo

Checked Set of nested primers







Concentrations

File: BRCA2 gene.seq

Constant Concentration Constant Volume

<input checked="" type="radio"/> Current +Oligo:	5.08 nmol/OD, 32.5 µg/OD	
<input type="radio"/> Current -Oligo:	4.67 nmol/OD, 30.9 µg/OD	
<input type="radio"/> Entire Sequence (ds):	0.001 nmol/OD, 48.1 µg/OD	
<input type="radio"/> Forward Primer:	5.98 nmol/OD, 35.0 µg/OD	
<input type="radio"/> Reverse Primer:	5.31 nmol/OD, 34.0 µg/OD	
<input type="radio"/> PCR Product (ds):	0.146 nmol/OD, 48.1 µg/OD	
<input type="radio"/> Upper Oligo:	4.83 nmol/OD, 31.2 µg/OD	
<input type="radio"/> Lower Oligo:	4.67 nmol/OD, 30.9 µg/OD	

µg

or OD(260)

or nmol

in µL

yields µM

AHP2 cDNA (TAIR database)

Sequence: AT3G29350.1 Date last modified 2007-04-17 Name AT3G29350.1 Tair
Accession Sequence:4010737427 Sequence Length (bp) 827

1 ACAATTCGCG AGAAAGACAA AACACAAGTT TCTTCTTCTT GGGATTGGCT
51 ATTTCCAGAA ATCCAAGTCA ATAATCAAAG TCCAAACAAA AAAATCCTCT
101 CCCAATCTCC GCTTCACTCT TCTCATGGAC GCTCTCATTG CTCAGCTTCA
151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG
201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT
251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT
301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC
351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT
401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC
451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT
501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG
551 ATCATTCAAG CTGGTGGTAT AGTTCCTCAA GTGGATATTA ACTAAAGAGA
601 CTAGTCCATA AGAAGAAAAA AGATGATGAC TTTCTTTCTT TAGTTTCTCT
651 TCTAAATTAT TTTGGATTTG GTGTTTGCTC AAAAACTCAA TAAAATATGT
701 GCAAAAAGAA ACAAAAACAA GTGATGGTTG TTTATAAATC AGTAGTATGT
751 ATTGTTTGAT CTCATCCGAG AAAATTGAAA CCATTGGACT AATGAATGTG
801 ATGATAATAT ATATTGGTTT GCTTCTG

101 CCCAATCTCC GCTTCACTCT TCTCATGGAC GCTCTCATTG CTCAGCTTCA
 151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG
 201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT
 251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT
 301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC
 351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT
 401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC
 451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT
 501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG
 551 ATCATTCAAG CTGGTGGTAT AGTTCCTCAA GTGGATATTA ACTAAAGAGA

EcoRI restriction site

5'.....G|AATTC.....3'

3'.....CTTAA|G.....5'

|

Design of primers

AHP2ex_up

5'- CCG GAA TTC ATG GAC GCT CTC ATT GCT CAG – 3'

AHP2ex_low

5'- CCG GAA TTC TTA GTT AAT ATC CAC TTG AGG – 3'

101 CCCAATCTCC GCTTCACTCT TCTC **ATGGAC GCTCTCATTG CTCAGCTTCA**
 151 GAGACAATTT CGTGATTACA CCATTTCTCT CTACCAACAG GGGTTTTTGG
 201 ATGATCAATT TACTGAGTTG AAAAAGCTAC AAGATGATGG AAGTCCTGAT
 251 TTTGTGTCTG AAGTGCTTTC ACTTTTCTTT GAAGATTGTG TGAAGCTTAT
 301 CAGTAACATG GCTAGAGCTT TGGACACGAC AGGAACTGTA GATTTTAGTC
 351 AGGTAGGTGC TAGTGTGCAT CAATTGAAGG GTAGTAGCTC AAGTGTTGGT
 401 GCCAAGAGGG TCAAAACTTT GTGTGTTAGC TTCAAGGAAT GTTGTGAAGC
 451 TAAGAACTAC GAAGGGTGTG TGAGATGTTT GCAGCAAGTG GATATTGAGT
 501 ACAAGGCGTT AAAGACAAAG CTTCAAGATA TGTTCAATCT TGAGAAACAG
 551 ATCATTCAAG CTGGTGGTAT AGTT **CCTCAA GTGGATATTA ACTAA**AGAGA

EcoRI restriction site

5'G|AATTC.....3'

3'CTTAA|G.....5'

|

Design of primers

AHP2ex_up

5'- CCG **GAA TTC** ATG GAC GCT CTC ATT GCT CAG – 3'

AHP2ex_low

5'- CCG **GAA TTC** TTA GTT AAT ATC CAC TTG AGG – 3'

LITERATURA

- Artificial DNA: Methods and Applications; Khudyakov, Y.E., Fields, W.A., Ed. (2003)
- PCR Primer: A Laboratory Manual (2003)
- OLIGO Primer analysis software, Version 7

Discovery is not in seeking new landscapes,
but in having new eyes...

Marcel Proust

Tato prezentace vznikla s podporou projektu **OP VK** „Rozvoj týmu pro výuku, výzkum a aplikace v oblasti funkční genomiky a proteomiky“ (CZ.1.07/2.3.00/09.0132)

Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.



INVESTICE DO ROZVOJE VZDĚLÁVÁNÍ

